Overland Park Surgical Suites First Outpatient Surgery Center In Region To Offer Robotics-Assisted Partial And Total Knee Replacement Surgery Using The NAVIO™ Surgical System

OVERLAND PARK, Kan.Dec 13, 2018 /PRNewswire/ — Overland Park Surgical Suites is a state of the art outpatient surgical center and is the first outpatient surgery center in the Midwest to offer patients a robotics-assisted alternative to traditional knee replacement surgery.

“We were eager to bring the NAVIO robotics-assisted surgery to the area,” said Scott Abraham, M.D., Orthopedic Surgeon and founder of Overland Park Surgical Suites, LLC. “This exacting technique is the preferred approach for most patients and we’ve seen dramatic surgical outcomes.”

The NAVIO Surgical System starts with an advanced computer system that gathers precise anatomic and alignment information about a damaged knee that a surgeon uses to create a specific surgical plan, according to Dr. Abraham.

“This extra layer of data collection is designed to ensure the knee procedure is performed as accurately as possible for the best long-term outcome,” he said.

Abraham has already performed more than 100 robotic-assisted partial and total knee replacements at Overland Park Surgical Suites and St. Joseph Medical Center, and draws patients to his practice from throughout KansasMissouri and Iowa. He said the NAVIO System is particularly well suited for active adults in their 40s and 50s who have developed knee problems, but have opted to put off surgery as a remedy.

“Knee replacement surgery has a controversial reputation,” Abraham added.

Unfortunately, this leads many patients to delay medical intervention because of concerns about invasive surgery, painful rehab and significant downtime. The NAVIO System helps offset these concerns with the improved accuracy and the potential for faster recovery, leading to the goal of improved surgical outcomes and increased patient satisfaction.

The first knee implant procedure was performed 50 years ago in 1968, according to the American Academy of Orthopaedic Surgeons. Now, more than 600,000 knee replacement surgeries are performed each year, making it one of the most in-demand surgical specialties in the country. Yet often, patients are dissatisfied with the outcome.

Not so for Beth Archer of Leawood, who in October was the first person in the state of Kansas to undergo a partial knee replacement using robotic surgical assistance at Overland Park Surgical Suites.

“I’d been living with knee pain for four years,” Archer said. “The quality of my life dramatically improved with my partial knee replacement done with the NAVIO Surgical System. I returned home immediately and was self-sufficient, had little pain and within a week I was walking without a cane or walker. I highly recommend this robotic surgery.”

Abraham added that the NAVIO benefits are many, yet robotic surgical-assist is still in its infancy.

“We’re proud that Overland Park Surgical Suites is the first outpatient surgery center in the region to offer this state of the art NAVIO knee replacement procedure,” Abraham said. “But we won’t be the last. In fact, we think this is the future of the surgical field. It puts the power of robotics in the skilled hand of the surgeon. And that means a better outcome for all our patients.”

For more information or to schedule a NAVIO consultation with Dr. Abraham, call APEX ORTHOPEDICS and Sports Medicine at 913-642-0200.

NOTE: Not all patients are candidates for surgery using the NAVIO Surgical System. Discuss your condition and implant options with your surgeon. Individual results of joint replacement vary. Implants may not produce the same feel or function as your original knee. There are potential risks with knee replacement surgery such as loosening, fracture, dislocation, wear and infection that may result in the need for additional surgery. NAVIO is not for everyone. Children, pregnant women, patients who have mental or neuromuscular disorders that do not allow control of the knee joint, and morbidly obese patients should not undergo a NAVIO procedure.

(www.OverlandParkSS.com
Overland Park Surgical Suites is a state-of-the-art, orthopedic outpatient surgical center in Overland Park, KS. It was established by clinical personnel to offer safe, high quality surgical care. It is one of the first surgery centers in the Kansas City area to perform outpatient total joint replacements and is licensed by the State of Kansas and accredited by The Joint Commission.

About Smith & Nephew: 
(www.RediscoverYourGo.com
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were more than $4.8 billion. Smith & Nephew is a member of the FTSE100.

TM is a Trademark of Smith & Nephew

Contact:      

Betsy Donnelly

Phone:         

913 208 5400

Email:           

Betsy@TrailheadMarketingTeam.com

SOURCE Overland Park Surgical Suites

Related Links

http://www.overlandparkss.com

In2Bones Expands Its Lead in PEEK Lower Extremity Implants with the Global Launch of the Unique PitStop® Subtalar Implant

December 11, 2018

MEMPHIS, Tenn.–(BUSINESS WIRE)–In2Bones Global, Inc. today announced the global launch of the unique, “see-through” PitStop®implant.

Manufactured from a high-performance polymer called polyether ether ketone (PEEK), the PitStop® Implant is used to help facilitate the surgical correction of progressive flat foot deformity in both pediatric and adult populations.

Flexible flatfoot is one of the most common deformities of the foot, often starting during adolescence and continuing into adulthood. The PitStop® Implant helps to restore the stability of a patient’s arch during the gait or walking process.

Several traditional metallic brands of subtalar implants are currently available today which can be limiting because of the excessive stiffness of the material compared to the adjacent bones, causing pain and biomechanical adaptation in some cases. PEEK has the benefit of being less stiff (softer) than metal and more similar to the elasticity of bone. The PEEK material in the PitStop® Implant may lead to increased and long-term patient tolerance.

Additionally, PEEK is radiolucent, meaning that it won’t show up on X-ray, something that traditional metal implants cannot do because metal absorbs X-rays and blocks the image underneath.

The Unique “see-through” PitStop® Implant demonstrates In2Bones’ commitment to expanding the extremities market by launching innovative technological advancements that improve surgical outcomes and patient care.

To support the commercial launch of the PitStop® Implant, In2Bones recently published the micro website, http://www.PitStop-Implant.com providing physicians and healthcare professionals with easy to access educational content. The materials on the site will include surgical animations and videos, surgical technique guides, case studies, patient support materials, and more.

For more information about In2Bones Global, Inc. extremity products, please visit www.In2Bones.com.

About In2Bones

Headquartered in Memphis, Tennessee, In2Bones is a global designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. For more information, visit www.in2bones.com.

Contacts

Jon Simon | Sr. Vice President of Marketing
In2Bones USA
M: 512.739.5793 • O: 901.260.7931 • F: 844-712-6637
Email: jsimon@i2b-usa.com
https://www.linkedin.com/company/22344175/

Bob Reed
Element-R Partners
630.579.1770
bob@rurelevant.com

NuVasive Grows Cervical Spinal Interbody Portfolio With PEEK Corpectomy Implant

SAN DIEGODec. 10, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded use of its Monolith®Corpectomy System, providing surgeons with a modular PEEK interbody solution for cervical corpectomy procedures.

The FDA 510(k) indications for expanded use of the Company’s Monolith Corpectomy System include procedures in the cervical spine (C3-C7 vertebral bodies) to treat a diseased or damaged vertebral body caused by fracture, tumors, osteomyelitis or to support reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissue in cervical degenerative disorders.

“Expanding the indicated use of our Monolith Corpectomy System to include cervical corpectomy procedures demonstrates the Company’s continued commitment to expanding our cervical spine interbody portfolio,” said Matt Link, president, Strategy, Technology and Corporate Development for NuVasive. “We are pleased to provide surgeons with a PEEK cervical interbody solution to help round out our cervical portfolio as we continue to advance our mission to improve patient lives.”

NuVasive’s Monolith Corpectomy System was initially cleared by the FDA for indicated use in thoracolumbar corpectomy procedures in 2015, offering a fully modular, imaging-friendly PEEK implant solution. The system is comprised of a monolithic core with modular endcaps that allow surgeons to customize the device to meet the patient’s specific anatomical requirements. The endcaps are available in multiple footprint and lordosis options intended to help maximize endplate coverage while addressing the surgeon’s alignment goals. The Monolith cage is constructed entirely from PEEK and includes radiographic markers, which provides increased clarity in postoperative x-rays and imaging, allowing surgeons to more easily assess fusion following procedures. The cage also includes large central graft apertures designed to help facilitate bony through-growth and fusion.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400-person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

IntraFuse Granted US Patent for FlexThread™ Intramedullary Fracture Fixation System

LOGAN, UtahDec. 6, 2018 /PRNewswire/ — IntraFuse, a start-up medical device company operated by Surgical Frontiers, is focused on advanced surgical devices for improving outcomes for orthopedic extremity procedures, announced today that the United States Patent and Trademark Office has recently granted the company a key patent related to its FlexThread Intramedullary Fracture Fixation system.

US Patent 10,136,929 entitled “Flexible Bone Implant” is the first patent to issue from the intellectual property portfolio held by the company that includes additional pending US and international patent applications. The patent covers the novel combination of an intramedullary rod with cross fixation on end and a flexible bone screw on the other end. This platform technology enables percutaneous, secure fracture fixation of long bones of the extremities, especially for curved bones or where the surgical technique requires an off-axis approach to the intramedullary canal.

The simple and elegant design is easier to implant and lower cost than today’s standard-of-care fracture fixation hardware. Incorporating IntraFuse’s proprietary FlexThread technology, the distal end of the implant is a flexible, intramedullary screw and the proximal end is a rigid, high-strength intramedullary rod. Upon insertion of the implant into the bone, the rigid rod portion of the implant spans and supports the fracture and the flexible screw portion bends as needed to thread into the intramedullary canal. With internal screw fixation on one side of the fracture and cross screw fixation through the rod on the other side of the fracture, proper bone alignment and length can be maintained during the healing period.

The FlexThread System is currently FDA 510(k) cleared for fibula and clavicle indications, and the FlexThread™ technology is in further development for additional indications, include fractures of the fifth metatarsal bone, also known as a Jones fracture.

IntraFuse is a development stage medical device company incubated and operated by Surgical Frontiers.

About Surgical Frontiers
Surgical Frontiers develops advanced surgical technologies that are ready for clinical use.   Focused primarily on musculoskeletal injuries and pathologies, the company collaborates with surgeons, industry, universities, and investors to bring advanced surgical technologies to the market that improve healthcare.

Media Contact:
Mr. Wade Fallin 
CEO
205883@email4pr.com 
http://surgicalfrontiers.com/intrafuse/ 
800-230-3710

SOURCE Surgical Frontiers

Related Links

http://surgicalfrontiers.com

Jupiter Medical Center is the first hospital in the southeastern United States to use SpineJack®

Jupiter, Florida, Dec. 05, 2018 (GLOBE NEWSWIRE) — JUPITER, FLORIDA (December 5, 2018) — Jupiter Medical Center is the first hospital in the southeastern United States to use SpineJack®, an implantable system that relieves the pain of acute vertebral compression fractures (VCFs), the most common fracture in patients with osteoporosis. The innovative device stabilizes and restores damaged vertebra to their original shape and height in a minimally invasive procedure that takes about 30 minutes.

“We take pride in offering the most advanced treatment options available,” said Don McKenna, president and chief executive officer of Jupiter Medical Center. “With this new technology, we are establishing Jupiter Medical Center as a leader in spine care not just locally, but nationally.”

Approved by the U.S. Food and Drug Administration in September, SpineJack® has been commercially available in Europe since 2008, with more than 70,000 units implanted worldwide.  It is produced domestically by the Stryker medical technology company.

“This is a revolutionary advancement for treating many patients suffering from acute osteoporotic vertebral compression fractures,” said Dr. Jeffrey Miller, medical director of Neuroendovascular Surgery and co-medical director of the Stroke Program at Jupiter Medical Center. “We know from its success in Europe over the last decade that it significantly improves the patient’s quality of life almost immediately.”

“SpineJack® is part of the expanding array of treatment options available in Jupiter Medical Center’s Interventional Radiology Program,” said Dr. Lee A. Fox, medical director of Imaging at Jupiter Medical Center. “Our program offers a full scope of advanced diagnostic procedures and minimally invasive therapies, and we are delighted to bring this new treatment option to our patients.”

Dr. Miller performed Jupiter Medical Center’s first SpineJack® on Nov. 6. His patient, 75-year-old Robert Fischer of North Palm Beach, is pleased with the outcome.  “It’s only been three weeks and I feel close to perfect – I’d say 95 percent,” said Fischer, who was diagnosed with osteoporosis earlier this year after he began suffering debilitating back pain.

VCFs are the most common medical condition experienced by those with osteoporosis or low bone mass. VCFs occur when the vertebral body in the spine collapses, which can lead to severe pain, spinal deformity and loss of height. The fractures more commonly occur in the middle (thoracic) and lower (lumbar) portions of the spine. While osteoporosis is the most common cause, these fractures may also be caused by trauma or metastatic tumors. The lifetime risk of osteoporotic fracture for those older than 50 years of age is one in two for women and one in four for men.

“SpineJack® treats back pain by targeting the cause and, as a result, it reduces the need for long-term use of pain medication,” Dr. Miller said. “In addition to enhancing our patients’ quality of life, this procedure could have a significant impact in the effort to combat opioid addiction.”

For decades the only nonsurgical treatments for VCFs were bed rest, bracing (which limits mobility) and pain medication. Vertebroplasty has been used since the early 1990s and more recently kyphoplasty, which has become a mainstay in the treatment of VCFs. In vertebroplasty, bone cement is injected directly into the fractured vertebra, where it quickly hardens and acts like an internal cast. In kyphoplasty, a balloon is inserted into the fracture to expand the space before the cement is added. Neither procedure restores the vertebral body to its full height.

SpineJack® was invented by a French physician whose inspiration was a scissor jack, the diamond-shaped car jack that is commonly used to lift a vehicle when changing a flat tire. Instead of a kyphoplasty balloon, the procedure utilizes a titanium implant that resembles a tiny scissor jack, which is deployed into the fractured vertebral body. Once in place, the SpineJack® is expanded to lift the compressed vertebra and restore it to its normal height. Two implants are used in the procedure, one on each side of the vertebral body. They are locked into the desired expanded position and bone cement is then injected to stabilize the vertebra. The implant becomes encapsulated with bone cement resulting in pain relief for the patient.

Fischer proved to be the ideal patient to undergo the first SpineJack® at Jupiter Medical Center.  In August, while spending the summer in Rhode Island, he underwent a kyphoplasty procedure to treat a VCF in his upper back. While wintering in South Florida just a few months later, he suffered a second VCF during a round of golf—this time in his lower back. His primary care physician referred him to Dr. Miller, who thought he would be a good candidate for SpineJack®.

“My recovery was much quicker,” he said. “With (kyphoplasty), that recovery took about 10 weeks before I felt as good as SpineJack® feels now, just three weeks later. I would definitely recommend it.”

Performed on an outpatient basis, the procedure is appropriate for patients who have been diagnosed with a VCF within four to six months of treatment. For more information, visit https://www.jupitermed.com/spinejack or call 561-263-2200.

About Jupiter Medical Center

A not-for-profit 327-bed regional medical center consisting of 207 private acute-care hospital beds and 120 long-term care, sub-acute rehabilitation and Hospice beds, Jupiter Medical Center is reimagining how to restore the community’s health and wellness. Award-winning physicians, world-class partnerships and innovative techniques and technology enable Jupiter Medical Center to provide a broad range of services with specialty concentrations in cardiology, oncology, imaging, orthopedics & spine, digestive health, emergency and pediatric services, lung & thoracic, women’s health, weight management and men’s health.

Founded in 1979, Jupiter Medical Center has approximately 1,650 team members, 637 physicians and 640 volunteers. Jupiter Medical Center continues to perform in the top 10 percent of hospitals for patient quality and satisfaction. For more information on Jupiter Medical Center, please call (561) 263-2234 or visit www.jupitermed.com.

Attachments

Ernestine Williams
Jupiter Medical Center
5612633852
Ernestine.Williams@jupitermed.com

FX Shoulder USA, Inc. to Begin Clinical Study on Stemless Reversed Total Shoulder

DALLASDecember 5, 2018 /PRNewswire/ —

FX Shoulder USA, Inc. will begin in December 2018 the FDA approved Investigational Device Exemption (IDE) clinical study of the Easytech Reversed stemless, a shoulder prosthesis, with its first implantation scheduled for December.

Easytech Reversed Stemless is an innovative shoulder arthroplasty implant that will be under clinical study with (9) sites and (12) surgeons across the U.S. participating. Building on the current success in France (home of FX Shoulder USA’sparent company, FX Solutions), where over 800 Easytech Stemless Reversed prostheses have been successfully implanted, FX Shoulder USA is slated to enroll patients at two (2) investigational sites in December and continue enrollment with additional sites beginning in January 2019.

“The Easytech Reversed may be exactly what the U.S. market is in need of, and a reversed stemless prosthesis could potentially be the future of shoulder arthroplasty,” said Baptiste Martin, CEO of FX Shoulder USA. “We are excited to begin our clinical study and enthusiastic to see the results with each successive case throughout. There is a lot of excitement among the surgeon investigators for Easytech Reversed,” he continued. In Europe, as per the article in Med Device Online dated April 11, 2018, stemless implants are projected to surpass stemmed implants by 2025.

Founded in 2011, FX Solutions has developed a large, unique and innovative range of prosthetic shoulder products, which include the Easytech Reversed Stemless. FX Solutions is now the second largest player in the French market, with more than 3,000 prostheses sold in 2018.

FX Shoulder USA, based in Dallas, Texas, is the direct provider of FX Solutions shoulder replacement devices in the U.S. FX Shoulder USA was founded in January 2018 and focuses exclusively on shoulder arthroplasty with a growing distribution network.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements, are based on our current plans and expectations and are subject to risks and uncertainties that might cause actual results to differ materially from those such statements express or imply. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to generate sufficient revenue to fund our commercial operations and development programs; and risks related to the development of Stemless Reversed shoulder prostheses, including regulatory approvals, mandates, oversight and other requirements. In this press release, forward looking statements include those concerning the development of the Stemless Reversed shoulder prosthesis, its safety and efficacy profile, its potential to benefit patients and our ability to make it available to those patients.  We disclaim any intention or duty to update forward-looking statements made in this press release.

http://www.fxshoulder.com

info@fxshoulder.com

SOURCE FX Shoulder USA

(Logo: https://mma.prnewswire.com/media/794130/FX_Shoulder_USA_Logo.jpg )

(Photo: https://mma.prnewswire.com/media/794131/FX_Shoulder.jpg )

Nexxt Spine Launches SAXXONY® Posterior Cervical Thoracic Spine System

December 04, 2018

NOBLESVILLE, Ind.–(BUSINESS WIRE)–Nexxt Spine LLC, a medical device company focused on designing, manufacturing, and distributing innovative spinal solutions, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and full commercial launch of its SAXXONY® Posterior Cervical Thoracic System—a system designed to stabilize cervical (C1 to C7) and thoracic (T1 to T3) spinal segments via posterior screw fixation in patients with degenerative disease, deformity, tumor, or trauma.

“The SAXXONY® System adds a robust posterior complement to our well received anterior cervical fixation offering as we continue to innovate and grow our fusion portfolio,” said Andy Elsbury, Nexxt Spine President.

The comprehensive offering includes standard and smooth shank screws available in a variety of diameter and length combinations, low profile cross connectors featuring multi-axis adjustability, and various configurations of offset, parallel, and axial connectors. The implant offering is complemented by streamlined instrumentation designed to ease rod placement and facilitate procedural efficiency.

In order to simplify longer complex constructs, the SAXXONY® Posterior Cervical Thoracic System has been designed to seamlessly link to the INERTIA® Pedicle Screw System with a variety of 3.5 to 5.5mm or 3.5 to 6.5mm rod-to-rod connectors and transition rods.

About Nexxt Spine

Nexxt Spine, LLC is a privately held medical device manufacturer dedicated to increasing procedural efficiency and patient outcomes through development of innovative products, manufactured on the most technologically advanced platforms, and utilizing irreproachable quality standards to treat painful and debilitating spinal pathologies. The company is growing rapidly and continues to recruit regional sales managers and independent distributors. For more information on Nexxt Spine and its products, please visit www.nexxtspine.com or email info@nexxtspine.com.

Contacts

Sarah Caito
scaito@nexxtspine.com

In2Bones Announces the Commercial Market Release of the CoLink® Afx Ankle Fracture Repair System

December 04, 2018

MEMPHIS, Tenn.–(BUSINESS WIRE)–In2Bones Global, Inc. today announced the U.S. commercial market release of the CoLink Afx® Ankle Fracture System. The system is a collection of five plate families that address traumatic fractures and osteotomies (removal of bone) of the ankle.

Anatomy specific plate options consist of Lateral Fibula, Posterior-Lateral Fibula, One-Third Tubular, Medial Tibia, and Posterior Tibia. Associated 2.7 and 3.5mm cortical screws are offered with innovative CoLink® VAL- Variable Angle Locking Technology.

The low profile anatomically, designed titanium plates are type II anodized. They provide a stronger smoother surface compared to standard color anodization used in most plates on the market. The ultra-thin plates, along with minimal prominence at the plate and screw head interface, provide additional protection against patients experiencing soft tissue irritation, which can occur with conventional trauma hardware.

“This comprehensive set allows me to fix any pattern of ankle fracture,” says Travis Hanson, MD of Houston Methodist Orthopedics and Sports Medicine.

“It has every type of plate and screw combination that I need,” he says. “The contoured design of the new CoLink® Afx System provides increased confidence that my patients will receive a plate that fits their specific anatomy. These are the most low profile plates that I have used around the ankle.”

“We’re very excited about the commercial market release of the CoLink® Afx System,” says Jon Simon, Sr. Vice President of Marketing at In2Bones. “Expanding our portfolio into the high-volume ankle fracture market with a truly best-in-class product provides tremendous growth opportunities for us heading into 2019.”

For more information about In2Bones Global, Inc. extremity products, please visit www.In2Bones.com.

About In2Bones

Headquartered in Memphis, Tennessee, In2Bones is a global designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. For more information, visit www.in2bones.com.

Contacts

Jon Simon | Sr. Vice President of Marketing
In2Bones USA
M: 512.739.5793 • O: 901.260.7931 • F: 844-712-6637
Email: jsimon@i2b-usa.com
https://www.linkedin.com/company/22344175/

Bob Reed
Element-R Partners
630.579.1770
bob@rurelevant.com

LimaCorporate Celebrates the Launch of the SMR TT Hybrid Glenoid, Expanding the Shoulder Portfolio

UDINE, ItalyNovember 30, 2018 /PRNewswire/ —

LimaCorporate is pleased to announce the launch of the SMR TT Hybrid Glenoid, the latest addition to the SMR Shoulder System.

The SMR Shoulder System is a total shoulder replacement designed to provide surgeons a wide range of options to address the different patients’ pathologies. There have been over 150,000 implants performed worldwide.

SMR TT Hybrid Glenoid is the first glenoid component with hybrid fixation convertible from anatomic to reverse. Being part of the SMR Shoulder System, SMR TT Hybrid Glenoid has been designed to provide an innovative solution for glenoid replacement allowing for proper soft tissues management thanks to an optimal range of sizes, mismatch options, and a reliable fixation supported by a combination of polyethylene and Trabecular Titanium, LimaCorporate’s proprietary 3D printed technology.

After a limited release phase, the SMR TT Hybrid Glenoid has been launched in the USA and New Zealand. SMR TT Hybrid Glenoid has also received the CE mark and will be officially launched next year in February during the Paris Shoulder Course.

This important accomplishment has been reached thanks to the contribution of a panel of experienced shoulder surgeons coming from all over the world.

This year, the SMR Shoulder System has been awarded by the Orthopaedic Data Evaluation Panel (ODEP) in the UK, two ratings (ODEP ratings can be found on odep.org.uk) a 10A rating for the SMR Reverse with Uncemented Fixation (Metal Glenosphere / Polyethylene Liner Combination), making it the only Reverse with a 10A rating available on the market and a 5A ODEP Rating – SMR Reverse HP with Uncemented Fixation (Polyethylene Glenosphere / Metal Liner Combination).

“We are very excited about the introduction of this innovative device on the market, which allows LimaCorporate to further complete the Shoulder portfolio, keeping its outstanding clinical heritage and approaching a new fixation philosophy,” said Luigi Ferrari, CEO of LimaCorporate.

About LimaCorporate

LimaCorporate is a global medical device company providing reconstructive and custom-made Orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.

For additional information on the Company, please visit: limacorporate.com

Limacorporate S.p.A.
Via Nazionale, 52
33038 Villanova di San Daniele del Friuli
Udine – Italy
T: +39-0432-945511
E: info@limacorporate.com

SOURCE Limacorporate S.p.A.

(Logo: https://mma.prnewswire.com/media/637371/Lima_Corporate_Logo.jpg )

In2Bones Commercializes CoLink® View “See-Through” Plating System

Memphis, Tenn., (November 27, 2018) – In2Bones Global, Inc. today announces the commercial launch of the CoLink® View Plating System.

CoLink® View Bone Plates, marketed under the CoLink® View brand name, incorporate a unique combination of titanium metal and a high-performance polymer called polyether ether ketone (PEEK).

The CoLink® View Plates offer transverse joint compression through an X-ray transparent PEEK hub. This allows the surgeon to watch the patient’s bone fusion site during the post-surgical healing process.

Traditional metal plates cannot do this because metal absorbs X-rays and blocks the image underneath. The “see-through” hub is unique to this new In2Bones plating system, and one of many device innovations designed by the company.

In addition to X-ray transparency, PEEK has a benefit of being less stiff than metal and more similar to the elasticity of bone. Bones need mechanical stress (elasticity) during the healing process. Stiffer, all metal implants may eliminate the positive elasticity and slow healing.

The CoLink® View is the sixth In2Bones PEEK-related implant system to reach commercialization. It demonstrates In2Bones’ commitment to expanding the extremities market by launching innovative technological advancements to improve surgical outcomes and patient care.

For more information about In2Bones Global, Inc. extremity products, please visit www.In2Bones.com.

About In2Bones
Headquartered in Memphis, Tennessee, In2Bones is a global designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. For more information, visit www.i2b-usa.com.

Safe-Harbor Statement:
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements reflect management’s current view of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” and other similar terms. The company wishes to caution readers that actual results might differ materially from those described in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties impacting the business, including increased competition, technical obsolescence, regulatory issues, general economic conditions and other risks.

Media Contacts:
Jon Simon | Sr. Vice President of Marketing
In2Bones USA
6000 Poplar Ave, Suite 115 Memphis, TN 38119
M: 512.739.5793 • O: 901.260.7931 • F: 844-712-6637
Email: jsimon@i2b-usa.com
https://www.linkedin.com/company/22344175/

Bob Reed
Element-R Partners
630.579.1770
bob@rurelevant.com